Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors

1st Edition - May 8, 2017

Write a review

  • Author: Giuseppe Tridente
  • eBook ISBN: 9780128094457
  • Hardcover ISBN: 9780128094006

Purchase options

Purchase options
DRM-free (PDF, EPub, Mobi)
Available
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement. This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.

Key Features

  • Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines
  • Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs
  • Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more

Readership

Intended for pharmacologists, clinicians and specialists including oncologists, drug safety control officials and drug developers and producers who are working to find effective molecules with the lowest adverse effects profiles; academics involved in drug safety issues and public health professionals

Table of Contents

  • Part I: General Aspects

    1. Introduction
    2. Protein and Lipid Kinases
    3. Kinase Inhibitors
    4. Adverse Events

    Part II: Oncotargeted Kinase Inhibitors

    5. Imatinib
    6. Gefitinib
    7. Erlotinib
    8. Sorafenib
    9. Sunitinib
    10. Dasatinib
    11. Lapatinib
    12. Nilotinib
    13. Pazopanib
    14. Vandetanib
    15. Vemurafenib
    16. Crizotinib
    17. Ruxolitinib
    18. Axitinib
    19. Bosutinib
    20. Regorafenib
    21. Cabozantinib
    22. Ponatinib
    23. Dabrafenib
    24. Trametinib
    25. Adatinib
    26. Idelalisib
    27. Ibrutinib

    Part III: Overview

    28. Kinase Inhibitors as Adverse Event Inducers
    29. Kinase Inhibitors as Drug Class Events
    30. Conclusion and Perspectives

Product details

  • No. of pages: 736
  • Language: English
  • Copyright: © Academic Press 2017
  • Published: May 8, 2017
  • Imprint: Academic Press
  • eBook ISBN: 9780128094457
  • Hardcover ISBN: 9780128094006

About the Author

Giuseppe Tridente

Professor Emeritus of Immunology and Pathology

School of Medicine and Surgery

Coordinator of the Teachers’ Committee for the Master in Translational Biomedicine

Universita degli Studi di Verona, Italy

Affiliations and Expertise

MD, Professor Emeritus of Immunology and Pathology, School of Medicine and Surgery, Universita degli Studi di Verona, Italy

Ratings and Reviews

Write a review

There are currently no reviews for "Adverse Events and Oncotargeted Kinase Inhibitors"